<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HCF6C0AC15E80467CBAB5109B4CE06988" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>116 HR 6660 IH: Limit Ongoing Shortages and Stabilize Supply Act of 2020</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2020-05-01</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">116th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 6660</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20200501">May 1, 2020</action-date><action-desc><sponsor name-id="B001303">Ms. Blunt Rochester</sponsor> (for herself and <cosponsor name-id="C001103">Mr. Carter of Georgia</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act to require the holders of approved applications for drugs to conduct a risk assessment to identify and evaluate risks to their supply chain and develop, maintain, and implement risk mitigation plans to address such risks, and for other purposes.</official-title></form><legis-body id="HD45C75A98469411B8AD11FD838CF5DD3" style="OLC"><section id="H2F969EF77F7C4B13B5800B8DCD7E2897" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Limit Ongoing Shortages and Stabilize Supply Act of 2020</short-title></quote> or the <quote><short-title>LOSS Act of 202</short-title>0</quote>.</text></section><section id="HAAA80FFF60A145D296E9406173401BBB"><enum>2.</enum><header>Risk assessments and risk mitigation plans for drugs</header><subsection id="HBA7AEC9316754BEEB8AF52C6879A112D"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Federal Food, Drug, and Cosmetic Act is amended by inserting after section 506C–1 of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356c-1">21 U.S.C. 356c–1</external-xref>) the following new section:</text><quoted-block style="OLC" id="H776CF64DA4D14FFA880DC7629824F005" display-inline="no-display-inline"><section id="HDA52F96C092345C3B1AEC8DDADFE0D84"><enum>506C–2.</enum><header>Risk assessments and risk mitigation plans for drugs</header><subsection id="HD307EC9BF2334D79B7367B607700C554"><enum>(a)</enum><header>Covered drug defined</header><text>In this section, the term <term>covered drug</term>—</text><paragraph id="H6AD7D7B956B1468B9C6B62F64E2FB3B0"><enum>(1)</enum><text>means a drug that—</text><subparagraph id="H53C529783AD247DB958E83467149560A"><enum>(A)</enum><text>is described in section 506C(a); or</text></subparagraph><subparagraph id="H566B549792D946B69105BF38E15C3994"><enum>(B)</enum><text>is included, or was included at any point during the preceding 5 years, in the drug shortage list in effect under section 506E; and</text></subparagraph></paragraph><paragraph id="H548DC50674824E8FB5C7FBA82E66717E"><enum>(2)</enum><text display-inline="yes-display-inline">includes any such drug that is not required to be approved pursuant to an application under subsection (b) or (j) of section 505 of this Act or subsection (a) or (k) of section 351 of the Public Health Service Act to be lawfully marketed.</text></paragraph></subsection><subsection id="H135376D4DC084464A482824471D6E2BA"><enum>(b)</enum><header>Requirement</header><text display-inline="yes-display-inline">The manufacturer of a covered drug shall—</text><paragraph id="H13B022E148324029A06D0D0FEBD07725"><enum>(1)</enum><text display-inline="yes-display-inline">conduct a risk assessment that identifies and evaluates risks to the supply of the drug, including vulnerabilities that would likely lead to a meaningful disruption in the supply of the drug in the United States;</text></paragraph><paragraph id="H1A37AAA6BA7141ED871225F2C87E1B9D"><enum>(2)</enum><text>develop and maintain a risk mitigation plan to ensure the supply of the drug during such a shortage; and</text></paragraph><paragraph id="H84C63E4587BA4753869657E321EB4BAF"><enum>(3)</enum><text>implement such plan during such a shortage.</text></paragraph></subsection><subsection id="H8042104C6B6B408E9457B38A82FCAE46"><enum>(c)</enum><header>Confidentiality</header><text>The Secretary shall—</text><paragraph id="H774689A70D6D4436B54E3F3FF6E805A6"><enum>(1)</enum><text>maintain the confidentiality of any risk assessment, and any risk mitigation plan, under this section; and</text></paragraph><paragraph id="H09E9C13500A1408D9B8BA5281EC430B3"><enum>(2)</enum><text>limit the use by the Secretary of information in such an assessment or plan to preventing, mitigating, or responding to a drug shortage.</text></paragraph></subsection><subsection id="HD3026F2CD2534EA182B1291B4A9F5080"><enum>(d)</enum><header>Guidance</header><text display-inline="yes-display-inline">The Secretary shall publish guidance on—</text><paragraph id="H9444FE8C78214139A837CF54A1415901"><enum>(1)</enum><text display-inline="yes-display-inline">how manufacturers should work with their supply chain partners in developing the required risk assessments and risk mitigation plans;</text></paragraph><paragraph id="H3C4BF510DD774CF8861861E1A4E6F46D"><enum>(2)</enum><text>the elements of a risk mitigation plan under this section; and</text></paragraph><paragraph id="HA7D36069F34B4221A89EBF52FB2E082C"><enum>(3)</enum><text>the form and manner of developing and maintaining such plan.</text></paragraph></subsection><subsection id="HD11FDA3C0C5C4A5F87AA74FA44661BDB"><enum>(e)</enum><header>Inspection</header><text>A risk mitigation plan under this section shall be subject to inspection and copying by the Secretary under section 704.</text></subsection><subsection id="HB04CCD275A91418F9999F5B4B4F787FB"><enum>(f)</enum><header>Expedited inspections and reviews</header><text display-inline="yes-display-inline">The Secretary may conduct an expedited inspection or review as described in section 506C(g) for the purpose of facilitating the implementation of a risk management plan developed pursuant to this section.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H203D8C6F62884199827E059CCD6FCE19"><enum>(b)</enum><header>Prohibited act</header><text>Section 301 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/331">21 U.S.C. 331</external-xref>) is amended by adding at the end the following:</text><quoted-block style="OLC" id="H3EDC1C48C01E4AAC8A071E645A8394E8" display-inline="no-display-inline"><subsection id="H68F91FBB315D42208B60E83EE3B73725"><enum>(fff)</enum><text display-inline="yes-display-inline">The failure to conduct a risk assessment, or to develop, maintain, and implement a risk mitigation plan, in accordance with section 506C–2.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="HB20F697E65254603BF15B2F22A000A40"><enum>(c)</enum><header>Applicability</header><text display-inline="yes-display-inline">The amendments made by this section apply beginning on the date that is 24 months after the date of enactment of this Act, except that the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall have discretion to allow persons subject to such amendments additional time to comply with such amendments as the Secretary determines necessary.</text></subsection></section><section id="H6A58118A98DA4C0D9D936BF93C260585"><enum>3.</enum><header>Discontinuance or interruption in production</header><subsection id="H60F5D73A68AE49B586AC45795807D1CE"><enum>(a)</enum><header>Active pharmaceutical ingredients</header><paragraph id="H70ECE19F025F47E59CE49D77E2C21E69"><enum>(1)</enum><header>Active pharmaceutical ingredients</header><text>Section 506C of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356c">21 U.S.C. 356c</external-xref>) is amended by adding at the end the following:</text><quoted-block style="OLC" id="HFBC197081B4E453881C465C5098C4042" display-inline="no-display-inline"><subsection id="HF39BC6E99B174AC0BD224AD2E523D14E"><enum>(j)</enum><header>Applicability with respect to active pharmaceutical ingredients</header><text display-inline="yes-display-inline">This section shall apply with respect to an active pharmaceutical ingredient in a drug described in subsection (a) in the same manner and to the same extent as this section applies with respect to a drug described in subsection (a), except that subsection (i) shall not apply with respect to active pharmaceutical ingredients.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph><paragraph id="HFAC8B99028E842EB914ECACCD29ECD73"><enum>(2)</enum><header>Guidance</header><subparagraph id="HE22B7CD91EF945FE9EB25A89A4297C04"><enum>(A)</enum><header>Issuance</header><text>Not later than 24 months after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall issue final guidance on implementing the amendment made by paragraph (1).</text></subparagraph><subparagraph id="H20CBC3AC3A274EE18BFF75BE154E047B"><enum>(B)</enum><header>Contents</header><text>The guidance required by subparagraph (A) shall specify—</text><clause id="HBC0A5510353B4CEBBC80AA37ED661E69"><enum>(i)</enum><text>the form and manner of the disclosures required by the amendment made by paragraph (1); and</text></clause><clause id="H7B0B1059B5E84C7CBE66106D1078E05B"><enum>(ii)</enum><text>the details that need to be included in such disclosures.</text></clause></subparagraph></paragraph></subsection><subsection id="HAE262A2C43AB49B697E2D531D688D87C"><enum>(b)</enum><header>Prohibited acts with respect to drugs and active pharmaceutical ingredients</header><text display-inline="yes-display-inline">Section 301 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/331">21 U.S.C. 331</external-xref>), as amended by section 2(b), is further amended by adding at the end the following:</text><quoted-block style="OLC" id="HB3BA44DD593F427AAF50CC9027EE979A" display-inline="no-display-inline"><subsection id="H31D795FD8FD0406285A383216EBD299E"><enum>(ggg)</enum><text display-inline="yes-display-inline">The failure of a manufacturer of a drug described in section 506C(a) or an active pharmaceutical ingredient of such a drug, without a reasonable basis as determined by the Secretary, to notify the Secretary of a permanent discontinuance or an interruption, and the reasons for such discontinuance or interruption, as required by section 506C.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H615E974D545B434F98D3A81085F440B2"><enum>(c)</enum><header>Applicability</header><text>The amendments made by subsections (a) and (b) apply beginning on the date that is 180 days after the date of enactment of this Act.</text></subsection></section></legis-body></bill> 

